25 results
424B5
BHVN
Biohaven Ltd.
16 Aug 24
Prospectus supplement for primary offering
4:21pm
-party payors and customers are subject to healthcare and other laws.
We may not obtain or maintain orphan drug designation or exclusivity for our product
424B5
BHVN
Biohaven Ltd.
19 Apr 24
Prospectus supplement for primary offering
6:02am
and customers are subject to federal and state healthcare and other laws.
We may not obtain or maintain orphan drug designation or exclusivity for our product
424B5
BHVN
Biohaven Ltd.
17 Apr 24
Prospectus supplement for primary offering
4:01pm
healthcare and other laws.
We may not obtain or maintain orphan drug designation or exclusivity for our product candidates.
Risks Related to Our
8-K
EX-99.1
zc5jq4
8 Jan 24
Regulation FD Disclosure
7:30am
424B5
lcjtbleiuqfmqyrxu
4 Oct 23
Prospectus supplement for primary offering
4:05pm
424B5
he7d0iu g1q585lg6y4
2 Oct 23
Prospectus supplement for primary offering
5:09pm
424B5
odcyacffnb
2 Oct 23
Prospectus supplement for primary offering
5:07pm
8-K
EX-99.1
8iy53s
27 Sep 23
Regulation FD Disclosure
6:58am
8-K
EX-99.1
l703j0 ih0zvtajr8b
28 Jul 23
Biohaven Provides Preliminary EEG Data Update for Kv7 Platform, Regulatory Update on Troriluzole and Other Corporate Updates
4:35pm
10-Q
qztsul360y
9 Nov 22
Quarterly report
4:19pm
424B4
ifj6rf1s a6j0p9hprj7
24 Oct 22
Prospectus supplement with pricing info
9:38am
S-1/A
039jr h1e
20 Oct 22
IPO registration (amended)
10:00am
S-1
vg6q5wely0ki5omgnsqt
18 Oct 22
IPO registration
4:03pm
DRS
ty9hnkw bf
11 Oct 22
Draft registration statement
12:00am
10-12B/A
EX-99.1
ynlw0va5xg9c
20 Sep 22
Registration of securities (amended)
6:30am
10-12B/A
EX-99.1
hivt si00lmbqqz2t1uv
14 Sep 22
Registration of securities (amended)
5:25pm
10-12B/A
EX-99.1
dkwz5pd6 qgtxob
7 Sep 22
Registration of securities (amended)
7:26am
10-12B/A
EX-99.1
n9q434qk5u2i
24 Aug 22
Registration of securities (amended)
5:03pm